We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

2 hedge funds and large institutions have $13 invested in Navidea Biopharmaceuticals Inc. in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding

Funds holding: 4 → 2 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

97% less capital invested

Capital invested by funds: $469 → $13 (-$456)

Holders
2
Holders Change
-2
Holders Change %
-50%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BBA
Baader Bank Aktiengesellschaft
Germany
-$435
2
ASN
Advisory Services Network
Georgia
-$14
3
BCMLT
Beacon Capital Management LLC (Tennessee)
Tennessee
-$1
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Parallel Advisors
California
$13 – – –
BBA
2
Baader Bank Aktiengesellschaft
Germany
– -$435 -10,630 Closed
ASN
3
Advisory Services Network
Georgia
– -$14 -250 Closed
BCMLT
4
Beacon Capital Management LLC (Tennessee)
Tennessee
– -$1 -10 Closed

NAVB Hedge Fund Activity: Q1 2024 in Review

2 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2024, worth a combined $13 — down 97% from $469 a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of NAVB and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Baader Bank Aktiengesellschaft, exiting entirely with an estimated $435 sold.

  • 2 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2024, down from 4 in Q4 2023.
  • Funds reported $13 of Navidea Biopharmaceuticals Inc. stock for Q1 2024, down 97% quarter-over-quarter.
  • 1 fund opened new Navidea Biopharmaceuticals Inc. positions in Q1 2024 and 3 closed out, a net change of -2 holders.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q1 2024 was Baader Bank Aktiengesellschaft, an estimated $435 sold.

Based on aggregated 13F filings for Q1 2024.